| Name | Title | Contact Details |
|---|
NCD is dedicated to improving lives by driving better health, providing an exceptional experience, and Spreading the Smile. As the costs of dental and vision insurance continue to increase across the country, our mission is to provide comprehensive dental and vision care thats accessible, quick to obtain, and simple to use. Whether youre uninsured or under-insured, NCD has a plan that fits your dental and vision needs.
Hyundai Motor Group Metaplant America (HMGMA) is an advanced automotive manufacturing facility located in Ellabell, Georgia. It serves as Hyundais third production hub in the U.S., complementing existing facilities in Alabama and Georgia. Designed as a Software Defined Factory, HMGMA integrates AI and robotics to support Hyundais vision for a technology-driven future in mobility. The facility spans 2,900 acres and will employ over 8,500 workers, with an additional 6,900 jobs created at off-site suppliers. HMGMA aims to produce 500,000 vehicles annually, including electric and hybrid models like the Hyundai IONIQ 5 and IONIQ 9. The plant represents a significant investment of approximately $12.6 billion, marking one of the largest economic development projects in Georgias history. HMGMA also emphasizes sustainability by utilizing hydrogen fuel-cell electric trucks for logistics, showcasing its commitment to environmentally responsible operations. The facility is expected to have a substantial economic impact, creating nearly 40,000 jobs in Georgia and supporting over 570,000 jobs nationwide.
Focus on joint success We are one of the international market and technology leaders for innovative laser marking systems. As a global brand and technology center for laser marking solutions, we are part of the Product Quality and Identification segment of the publicly traded Veralto Corporation. FOBA is a leader in camera-based precision systems, machines and workflows for laser marking and engraving. We help our customers to ensure the traceability of their products, to protect their quality and brands, to design products and to respond to trends and regulations at an early stage – especially in our key markets of medical technology and the automotive, aerospace and electronics industries. With decades of laser application expertise, technology leadership in camera-assisted laser marking and consistent customer and service orientation, we can refer to several thousand successfully installed systems worldwide. https://www.fobalaser.com Imprint: https://www.fobalaser.com/legal-notice/ FOBA Laser Marking + Engraving Brand of ALLTEC Angewandte Laserlicht Technologie GmbH
Reliable Controls manufactures simple, flexible, sustainable building automation solutions that balance comfort and efficiency while reducing greenhouse gas emissions in buildings around the world. Our goal to help others achieve their goals begins by listening. We hear the World Green Building Councils call to businesses, organizations, cities, states, and regions to reach net-zero operation by 2050. The next 30 years are critical. In the world of building automation systems, that means you want products that are built responsibly and built to last. Reliable Controls technology is backward compatible, better by design, and supported by responsible recycling. Install our controllers now, and they will thrive for decades. Thats a sustainable return on investment. This dedication to multigenerational success is unique to our brand and reflects our pledge to sustainability. Its with purpose that we refer to our lineup of controllers or sensors as a family; each generation adds value, and nothing is rendered obsolete. We also take great pride in creating a healthy, sustainable working environment for our employees—as evidenced in our Canadas Greenest Employer Award honors in 2020.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.